HUMA
NASDAQHumacyte Inc.
News25/Ratings11
News · 26 weeks58+75%
2025-12-282026-06-21
Mix4490d
- Insider15(34%)
- SEC Filings11(25%)
- Other10(23%)
- Offering4(9%)
- Leadership3(7%)
- Earnings1(2%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Humacyte Inc.SCHEDULE 13G - Humacyte, Inc. (0001818382) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.SCHEDULE 13D/A - Humacyte, Inc. (0001818382) (Subject)
- PRHumacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care – – Company to hold investor event today, June 15th, at 5:00 p.m. ET – DURHAM, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, presented detailed results from its V012 Phase 3 study showing that the Company's bioengineered blood vessel – the acellular tissue engineered vessel, o
- INSIDERSEC Form 4 filed by Director Windham-Bannister Susan Richards4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Constantino Michael T.4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Wallace Max N.4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO and Director Niklason Laura E4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Sebelius Kathleen4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Jones Keith Anthony4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Green Charles Bruce4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Seimetz Diane4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Bamforth John Philip4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Brown Emery N.4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERSEC Form 4 filed by Director Dougan Brady W4 - Humacyte, Inc. (0001818382) (Issuer)
- PRHumacyte, Inc. Announces Pricing of Public Offering of Common StockDURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition,
- SECSEC Form 424B5 filed by Humacyte Inc.424B5 - Humacyte, Inc. (0001818382) (Filer)
- SECHumacyte Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Humacyte, Inc. (0001818382) (Filer)
- PRHumacyte, Inc. Announces Proposed Public Offering of Common StockDURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock are being offered by Humacyte. Barclays, BTIG and Titan Partners, a division of American Capital Partners, are acting as joint book-running managers for th
- PRHumacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012's primary endpoint and was observed to have superior catheter-free days (p=0.00070) compared to autologous arteriovenous (AV) fistula, the current standard of care - - The ATEV's ability to reduce time on catheter has the potential to improve patient outcomes and lower the burden of dialysis costs on the healthcare system. - DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at
- SECHumacyte Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Humacyte, Inc. (0001818382) (Filer)
- SECHumacyte Inc. filed SEC Form 8-K: Other Events8-K - Humacyte, Inc. (0001818382) (Filer)
- PRHumacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - - Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June - DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research providing evidence of self-repair of
- INSIDERDirector Sebelius Kathleen bought $50,000 worth of shares (56,818 units at $0.88), increasing direct ownership by 62% to 148,025 units (SEC Form 4)4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERDirector Constantino Michael T. bought $9,840 worth of shares (11,000 units at $0.89), increasing direct ownership by 33% to 43,950 units (SEC Form 4)4 - Humacyte, Inc. (0001818382) (Issuer)
- INSIDERCFO and Chief Corp. Dev. Off Sander Dale A. sold $41,147 worth of shares (45,887 units at $0.90) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 267,213 units (SEC Form 4) to satisfy tax liability4 - Humacyte, Inc. (0001818382) (Issuer)
HUMA FAQ
6 questionsWhere does HUMA stock trade?
Humacyte Inc. (HUMA) is listed on NASDAQ.What sector and industry is HUMA in?
Humacyte Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Humacyte Inc. go public?
Humacyte Inc. (HUMA) completed its IPO in 2020.What are analysts saying about HUMA?
Humacyte Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $350.00 price target on 2025-08-27. Recent price targets range from $350.00 to $1700.00.What companies are similar to HUMA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare HUMA side-by-side with any of them on Quantisnow.How can I track HUMA on Quantisnow?
Quantisnow aggregates Humacyte Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HUMA to receive live email and push alerts on every new disclosure.